EN DE
Watch Transgene Biotek Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Transgene Biotek Limited (526139) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Transgene Biotek Limited stock ₹1.65, price ₹2.52, that is 34.5% below the price, quality 33 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Health Care IN

TB Transgene Biotek Limited logo Thin data Nov 10, 2026

Transgene Biotek Limited

526139 · BSE
Expensive, weak quality

Our calculation puts a fair price 35% below what the stock costs today.

Mixed Growth (revenue 5y +4.5 %/yr in INR)
Moderate debt
Fair value ₹1.65 · Overvalued
Quality 33/100
Negative free cash flow
Trails peers (2/6)
Narrow moat 12/100
Thin data
Estimate⚠ Thinly traded
Watch Transgene Biotek Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹11.98 ₹1.97 Fair Value ₹1.65 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ₹1.97 – ₹11.98 · fair‑value band ₹1.24 – ₹2.06 · the ₹2.52 price screens above the ₹1.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Transgene Biotek in your weekly email

Every Wednesday you see whether Transgene Biotek is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Transgene Biotek Limited engages in the provision of research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics.

Show moreShow less

The company offers TrabiDHA for use in health foods, baby food/formulas, health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption.

The company was incorporated in 1990 and is based in Sangareddy, India.

Stock analysis

Transgene Biotek Limited (526139) currently trades at ₹2.52, while our estimate is ₹1.65, 35% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹1.24 (bear) to ₹2.06 (bull), the price of ₹2.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Health Care sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Transgene Biotek Limited reported revenue of ₹2.1M in FY2026 versus ₹867K in FY2022, a compound +24.9%/yr. Reported net income was −₹16.5M in FY2026.

Key figures

Market cap ₹308M (≈ $3.3M) Micro · EPS (TTM) ₹−1.48 · Return on equity −32.9% · Return on assets (EBIT) −2.6% (5-year average) · Operating margin 304,919% · Revenue (TTM) −₹34.9K · Free cash flow −₹113K · Net debt ₹171M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 35% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Health Care peers we cover trades at −7% fair-value upside, at −35%, 526139 screens richer than that median.

Fair Value

Bear ₹1.24 Fair Value ₹1.65 Bull ₹2.06
Price ₹2.52 · Downside -34.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 0
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−19.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Start year 2021 (pandemic). Over 10 years: +1.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,154.7% (2021) → −351.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

526139 screens overvalued: fair value 35% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Transgene Biotek Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside −34.5% · Below median
Profitability
Return on assets −1.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.81× · Highest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)59 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 526139
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 526139
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 526139
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 526139
argenx SE ARGX $971.55 $908.40 −7% vs 526139
CSL Limited CSL A$201.68 A$181.40 −10% vs 526139
Moderna, Inc MRNA $250.83 $158.70 −37% vs 526139
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 526139
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 526139
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 526139

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Transgene Biotek Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Transgene Biotek Limited Fair Value". https://www.fairvalue-calculator.com/stock/526139

Frequently asked questions

Is Transgene Biotek Limited (526139) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ₹1.65 versus a price of ₹2.52, about 35% lower (overvalued).
What is the fair value of 526139?
Our estimate for Transgene Biotek Limited is ₹1.65 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹2.52.
What is the quality score of 526139?
Transgene Biotek Limited has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Transgene Biotek Limited (526139)?
Our calculated price target is the estimate of ₹1.65 (as of Nov 10, 2026). Cautious scenario ₹1.24, optimistic scenario ₹2.06. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Transgene Biotek Limited stock forecast for 2026?
Our estimate puts fair value at ₹1.65, about 35% lower versus a price of ₹2.52 (overvalued). Cautious scenario ₹1.24, optimistic scenario ₹2.06. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Transgene Biotek Limited (526139)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Transgene Biotek Limited it is ₹1.65 per share (as of Nov 10, 2026), against a price of ₹2.52.
Is Transgene Biotek Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 526139 trades above its calculated fair value: price ₹2.52, fair value ₹1.65, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 526139?
No. The price is what the market pays today (₹2.52); the fair value is what the company's own numbers justify (₹1.65). For Transgene Biotek Limited the two are ₹0.8700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Transgene Biotek Limited worth?
The market values Transgene Biotek Limited at about ₹308M (market capitalisation, as of Nov 10, 2026). Per share that is ₹2.52; our models calculate a fair value of ₹1.65 per share.
What do the bullish and bearish scenarios say about 526139?
Our models span a range for Transgene Biotek Limited: cautious scenario ₹1.24, base ₹1.65, optimistic ₹2.06 per share (as of Nov 10, 2026, price ₹2.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Transgene Biotek Limited (526139)?
Balance-sheet figures for Transgene Biotek Limited (as of Nov 10, 2026): return on equity −32.9%, debt of 0.81 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 526139 from its 52-week high?
Transgene Biotek Limited trades at ₹2.52, about 35% below its 52-week high of ₹3.90 and 28% above the low of ₹1.97 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1.65 is for.
Which stocks are comparable to Transgene Biotek Limited?
From the same area (Health Care) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Transgene Biotek Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹2.52, calculated fair value ₹1.65 (−35%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Transgene Biotek Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Transgene Biotek Limited (526139)?
The closing price on Nov 9, 2026 was ₹2.52. Our estimate is ₹1.65, about 35% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Transgene Biotek Limited right now?
The price sits above even our optimistic bull case (₹2.06). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Transgene Biotek Limited

How large is the market capitalisation of Transgene Biotek Limited (526139)?
The market capitalisation of Transgene Biotek Limited is ₹308M (≈ $3.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Transgene Biotek Limited (526139)?
Earnings per share at Transgene Biotek Limited are ₹−1.48. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Transgene Biotek Limited (526139)?
The return on equity (ROE) of Transgene Biotek Limited is −32.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Transgene Biotek Limited (526139)?
On an EBIT basis the return on assets of Transgene Biotek Limited is −2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Transgene Biotek Limited (526139)?
The operating margin of Transgene Biotek Limited is 304,919% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does Transgene Biotek Limited (526139) generate?
Transgene Biotek Limited generates revenue of −₹34.9K (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How much free cash flow does Transgene Biotek Limited (526139) generate?
The free cash flow of Transgene Biotek Limited is −₹113K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Transgene Biotek Limited (526139) carry?
The net debt of Transgene Biotek Limited is ₹171M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Transgene Biotek Limited in the live analysis

One click puts Transgene Biotek Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.